

CURRICULUM VITAE

Michael Grant Agadjanyan, Ph.D., D.Sc.

Personal Data:

Current Office The Institute for Molecular Medicine
Address: 16371 Gothard Street, H, Huntington Beach,
 CA 92647-3652
 Tel: (714) 596-7821
 FAX: (714) 596-3791

Education:

1979 Ph.D., Immunology and Immunochemistry
 Gamaleya Institute of Epidemiology and Microbiology,
 Moscow, Russia
1989 D.Sc. (Doctor of Science is the Highest Degree in Russia and several EU
 Countries), Immunology and Virology, Institute of Viral Preparation, Moscow, Russia

Professional Experience and Appointments:

1975 -1978 Graduate Student the Gamaleya Institute, Moscow, USSR/Russia (Supervisor
 Aaron Gurvich, Ph.D., D.Sc.)
1979-1983 Scientist, Senior Scientist Immunology and Immunochemistry Laboratory the
 Gamaleya Institute USSR Academy of Medicine, Moscow, USSR/Russia
1983 -1989 Assistant Professor/Associate Professor, Immunochemistry Laboratory, the Institute
 for Viral Preparation USSR Academy of Medicine, Moscow, Russia
1989 -1992 Professor Institute for Viral Preparation/Mechnikov's Institute for Vaccine and Sera,
 USSR Academy of Medicine, Moscow
1992 -1993 Visiting Professor (Faculty Position), Wistar Institute, Philadelphia, PA,
 USA 19014
1993-2000 Visiting Professor (Faculty Position), Department of Pathology Laboratory of
 Medicine, University of Pennsylvania, Philadelphia, PA, USA 19014
2000-2003 Professor, Head of Laboratory for Molecular Immunology, Institute for Molecular
 Medicine, Huntington Beach, CA, USA 92647
2003-present Vice-President, Head of Department of Molecular Immunology, Professor, Institute
 for Molecular Medicine, Huntington Beach, CA, USA 92647

2005-present Adjunct Research Professor (Faculty Position), Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697

Postgraduate Training:

1979- 1983 The Gamaleya Institute of Epidemiology and Microbiology, Laboratory of Professor Aron Gurvich, Department of Immunology, Laboratory of Biosynthesis of Antibodies

Awards, Honors, and Membership in Professional Societies:

1970 Armenian's Research Fellowship Award, USSR
1971 Travel Award, University of Yerevan, Armenia
1972 Young Investigator Award University of Moscow, USSR
1975 Outstanding Junior Member Award, USSR Academy of Medicine, Moscow
1978 Institute of Gamaleya, Junior Investigator Award, USSR Academy of Medicine, Moscow
1980 Member of Program Committee for Russian Immunology Meeting Suzdal, Russia.
1981 USSR Academy of Medicine Research Fund Award, Moscow
1980-Present Member of USSR/Russian Biochemical Society
1982-Present Member of USSR/Russian Immunological Society
1983-1992 Reviewer of the Journal *Voprosi Virusologii*, Moscow and Prague
1985 Moscow Institute for Viral Preparation Foundation First Award
1986 Member of Program Committee for Russian Immunology Society Meeting Tbilisi, Georgia.
1988 Research Council Academy of Medicine, USSR
1988 Moscow Institute for Viral Preparation Foundation First Award
1989-1994 Reviewer of the Journal *Immunology*, Moscow, Russia
1990-1992 Member of Committee of Experts for Russian Academy of Medicine Infection diseases (include AIDS) Foundation
1989-1992 Russian Academy of Medicine Immunology Foundation Award
1989-1992 Member of Doctoral Committee at the Gamaleya Institute of Epidemiology, Microbiology and Immunology.
1989-1992 Russian Academy of Sciences Biotechnology Foundation Award
1989-1992 Member of Scientific Advisory Board of Nearmedic Inc., London/Moscow.
1990-1992 Member of Doctoral Committee at Gabrichevskogo Institute of Epidemiology and Microbiology
1992-Present Reviewer for the journals *DNA and Cell Biology*, *Immunology*, and *Journal of Clinical Investigation* USA.
1994-1998 Member of International Retrovirus Association: HTLV and Related Viruses
1994-Present Member of American Association of Immunology
1998-Present Member of Russian Academy of Natural Sciences
1998-Present Multiple R21 and R01 NIH Awards; CRDF Award; Susan Komen foundation Award; Alzheimer's Association Awards
1998 Keynote Speaker at AE Gurvich's Seminar, Institute of Epidemiology and Microbiology, Russian Academy of Medicine, Moscow

2000	Honorable Doctor of Armenian Academy of Science
2000-Present	Grant Reviewer NIH/NIAID, NIA, NINDS
2007-Present	American Society for Neuroscience

U.S. Patents

1. Nucleic acids encoding mutant human CD80 and compositions comprising the same human CD80 United States Patent 7446189 (licensed to Wyeth/Pfizer, USA)
2. Preventive Cancer Vaccine Based on Brother of Regulator of Imprinted Sites Molecule (BORIS) PCT/WO 2005/021029 A2 (worldwide patents licensed to UniVax, USA)
3. Proteins for use in diagnosing and treating infection and disease, PCT/US2007/02194 (licensed to Viral Genetics Inc, USA)
4. Epitope Vaccine for Prevention and Reversion of AD Pathology, PCT/US2008/010186 (licensed Russian patent to Nearmedic plus)
5. Composition and methods related to diseases associated with deposits of amyloid, tau, and/or a-synuclein (US 61,691,607; US61,792,770; US PCT 13,55874. Licensed to Neuroimmune, LLC)
6. Anti-tau antibodies and composition for and methods of making and using in treatment, diagnosis and monitoring of tauopathies (US 61,759,216; US 61,763,358; US Patent 13/839,135. Licensed to AGP Therapeutics, LLC)

Past and Present Trainees:

(More than 15 undergraduate students from Moscow State University 1988-1992)

Tatevic Megrabian	Ph.D, 5/80 - 8/85. Induction and detection of T and B-cells immune responses <u>in vivo</u> and <u>in vitro</u> against viral antigens
Irina Smirnova	MD, 11/84 - 7/91. Induction and detection of humoral immune responses <u>in vitro</u> and <u>in vivo</u> (in adoptive transfer system) against T-independent bacterial antigens types 1 and 2
Nadezda Logunova	Ph.D, 1/88 - 5/90. Generation and selection of monoclonal antibodies against mouse cellular antigens
Alexander Maklakov	MD, 7/87-11/91. Detection by ELISA and FACS anti-idiotypic antibodies against antibodies to influenza virus PR8/34
Michael Chattergon	Undergraduate Student 8/93-10/95. Generation of monoclonal antibodies specific to novel 80kD putative cellular fusogenic receptor for HTLV-I/II, cellular ELISA, immunoprecipitation, Western Blotting
Ara Chalian	MD, 8/93-11/94. Analysis of cDNA lambda ZAP-blu library, isolation and purification of DNA, transfection of eukaryotic cells
Dan McCallus	Ph.D. 3/94-5/95. Detection of HIV and SIV proteins in transfected eukaryotic cells by immunoprecipitation and FACS assay
Arthur Cho	Undergraduate Student 8/94-2/85. Induction and detection of humoral immune responses against HIV-2 envelop, and tat and rev proteins of HIV-I by ELISA after cDNA inoculation
Neil Trivedi	Undergraduate Student 9/95-5/97. Generation of immune responsesto HIV-2 env. T-cell proliferation, immunoprecipitation, Western Blotting
Mosi Bennett	Undergraduate Student 9/94-6/96. Detection of neutralizing antibodies against HTLV novel cellular receptor. Syncytia formation and virus titration in vitro
Wilton Levine	Undergraduate Student 9/95-9/96. Generation of immune responsesto

	HIV-2 env. Immunization in vivo by cDNA, ELISA, Western Blotting, cell free infection
Michael Appel	Undergraduate Student 9/96-9/98. Generation of immune responses to SIVgag/pol. Purification of cDNA and immunization in vivo by these
Khady Loo	Undergraduate Student 9/98-6/99. Generation of immune responses to SIVgag/pol. Purification of cDNA and immunization in vivo by these cDNA preparations, ELISPOT
Tzvete Dentchev	7/97-5/00. Mechanism of T-cell activation and role of CD80/86 molecules in this process
Gregory Arutunyan	12/99-3/00. Mechanism of T-cell activation and role of CD80/86 molecules in this process
Michael Chattergoon	9/99-5/00. Mechanism of T-cell activation and role of CD80/86 molecules in this process
Anahit Ghochikyan	Ph.D. 6/00-Present. Generation of potent cellular immune responses against viral, tumor, peptide, and bacterial antigens. Clinical trials with mt DNA and PBMC's.
Vitali Vasilevko	M.S. 9/00-9/03 Generation of potent cellular immune responses against viral, tumor, and bacterial antigens and Clinical trials with NT factor and Echinacea
Nina Movsesyan	Ph.D. 1/02-4/06. Generation of vaccine against Alzheimer's disease. Preparation of DNA constructs, immunization of mice, detection of cellular and humoral immune responses
Davit Babikyan	M.S. 1/02-5/04. Generation of vaccine against Alzheimer's disease. Preparation of DNA constructs, immunization of mice, detection of cellular and humoral immune responses
Nadja Sadzikava	M.D. 11/01-9/03. Animal studies. Detection of NK cells in PBMCs, generation of plasmids, immunization of mice, etc.
Mikayel Mkrtichyan	M.S. 02/04-10/09. The generation and detection of anti-BORIS immune responses in 4T1 mouse model of breast cancer
Gregory Mamikon	Ph.D. 05/03-05/06. TNP clinical and pre-clinical studies. The purification of anti-amyloid antibodies and detection their functions
Hayk Davtyan	Ph.D. 09/06-Present. Generation of vaccines and detection systems for CDC Pathogens A, B, and C
Davit Hovhannes	Bachelor student. 02/09-05/09. Analyzing of therapeutic effect of long-term expression of scFv anti-Abeta antibody in mice
Jivan Khlghat	Master student. 02/09-01/10. The generation of DNA based epitope vaccine against breast cancer
Dmitry Bolotin	Master student. 02/10-06/10. Development of BORIS based vaccine delivered by dendritic cells or plasmid encoding this cancer-testis antigen against metastatic mouse mammary
Mikhail Shugay	Master student. 02/10-Present. Development of BORIS based vaccine delivered by dendritic cells against metastatic mouse mammary
Arpine Davtyan	MS. 07/10-Present. Development of VRP-based anti-tumor vaccine in a mouse model of breast cancer. Testing TLR4 agonist in 4T1 mouse model of breast cancer.
Armine Hovakimyan	MS. 07/10-Present. The generation of protein and DNA based epitope vaccines against AD. Detection of humoral and cellular immune responses in mice, rats, rabbits monkeys.
Karen Zagorski, MS	05/12-Present. The generation of multiple DNA and recombinant proteins based on universal MultiTEP platform and testing it in mice, rabbits and monkeys.

- K. Kazarian, Ph.D. 08/14-Present. The generation of double transgenic mice (A β /tau) and analyses of Armanezumab in different Tau/Tg mice
- Max Antonenko, MS 09/15-Present. Testing various new MultiTEP-based vaccines fused with post-translational B cell antigenic epitopes (pyrogultamated Ab, phosphorylated Tau, Acetylated Tau, etc)

Teaching Experience:

1988-1991 - Immunology/Virology Course. Delivered lectures on humoral and cellular immune responses against human pathogens. Pirogov's Institute of the Russian Academy of Medicine and Moscow State University 35 hrs lecture per year for a period of 3 years.

1993-Present - Supervision of undergraduate students and graduate students at Pathology Department at the University of Pennsylvania, and at IMM.

1980-Present The lecturer at different universities and research institutions as well as international and national conferences.

Lectures By Invitation:

1985-1990 Moscow, Novosibirsk, Kiev, Yerevan and other cities of former USSR. Lecture Topics:
 (1) Mechanisms of the antigen dependent non-specific immune response;
 (2) T and B-cells interaction and generation of the antibodies and antigen dependent non-specific immunoglobulins *in vivo* and *in vitro*;
 (3) Activation of the B-lymphocytes, role T-cells factors for specific and non-specific immune responses

June 1986: University of Seged, Hungary
 Anti-idiotypic regulation of the immune response against influenza virus

September 1988: CRC London, UK.
 Specific approaches for the generation monoclonal antibodies against the constant region of Env glycoprotein of HIV-1

Oct 1988: University of Seged and Institute of Biochemistry in Budapest, Hungary. Induction antibodies against influenza and adenovirus type 6 *in vitro*

April 1989: The Wistar Institute, Philadelphia, USA
 Antigen presenting cells infected by HIV-I and their potential killing of CD4 positive cells

Nov 1990: CRC and Holms Medicus London, UK
 Possible mechanisms of depletion a CD4 positive T-cells in a HIV-1 infected patient

March 1991: The University of Pennsylvania, Philadelphia, USA.
 Generation monoclonal antibodies against recombinant gp 120 HIV-III_B; Using FACS for detection of the preparation inhibiting the interaction between

HIV and CD4 receptor

- June 1994: Institute of Viral Preparation, Russian Academy of Medicine, Moscow
A novel 80kD antigen the HTLV-I/II putative fusogenic cellular receptor and generation of monoclonal antibodies against this antigen.
- Dec 1995: Pro/Neuron Inc., Washington DC, USA
Nucleic acid vaccine against human retroviruses.
- March 1996: Institute of Tuberculosis Russian Ministry of Health, Moscow, Russia.
Nucleic acid inoculation novel method for vaccination against HIV-I/II
- April 1996: Public Health Research Institute, New York, USA
Nucleic acid vaccination against retroviruses.
- May 1996: Naval Medical Research Institute, Rockville, MD, USA
Novel Genetic Approaches for Vaccines
- February 1997: Thomas Jefferson University, Cancer Center, Philadelphia, USA
DNA-based HIV vaccine.
- Nov 1997: Tumor Biology Section, Head and Neck Surgery Branch, NIDCD/NIH, Bethesda, MD, USA
Novel Genetic Methodology for Generation of anti-Viral and anti-Tumor Vaccines.
- January 1998: Institute of Biomedical Investigations, UNAM, Mexico City, Mexico
DNA immunization from mice to men
- June 2002: Armenian Academy of Sciences, Yerevan, Armenia
The future of DNA vaccines
- Nov 2000: WHO laboratory at the Institute of Tuberculosis, Moscow, Russia
The generation of TB vaccine using B7 costimulatory molecules as molecular adjuvant
- Dec 2003: The Institute for Brain Aging and Dementia, UCI, Irvine, USA
The immunotherapy of Alzheimer's disease: DNA, epitope, and mimotope vaccine approaches
- April 2005: University of California, Irvine, USA
Epitope vaccine in wildtype and three different types of APP/Tg mice: immunological studies and A β pathology
- May 2006: Harvard Medical School, Harvard University, Boston, MS, USA
Prototype Alzheimer's Disease Vaccine
- May 2006: Viral genetics, Inc., Harvard University, Boston, MS, USA
Detection of the active components of calf thymus nuclear proteins (TNP)

- Oct 2006: Gerontology Research Center at the NIA, NIH, MA, USA
Prototype Epitope Vaccines based on Peptides and Nucleic Acids.
- Nov 2007: Ichor Inc., San-Diego, USA
DNA vaccines for AD, problems and solutions
- April 2008: Pharmexa, Inc., San Diego, USA
Prototype AD Vaccine
- Sept 2008: University of Pittsburgh, Vaccine res Center PA, USA
Vaccine Research Center, Strategies in AD Vaccine Development: Prophylactic vs Therapeutic Vaccine
- October 2008: University of Nebraska Medical School, USA
Second Generation DNA based AD Vaccine
- January 2009: Lundbeck A/G, New Jersey, USA
Protein, peptide, and DNA-based Epitope Vaccines for Alzheimer's Disease
- April 2009: Ichor Medical Systems and H. Lundbeck A/S, San-Diego, USA
Strategies in AD vaccine development: prophylactic vs therapeutic Vaccine
- August 2009: Russian Academy of Medicine, Moscow, Russia
BORIS as a Novel Tumor Antigen for treatment of BrCA
- January 2009: Viral genetics Inc., Azusa, CA, USA
Second Generation DNA AD epitope Vaccine
- February 2010: GMB Bio, Inc., San-Francisco, USA
Delivery of vaccines by biodegradable nanoparticles
- Aug/Sep 2010: Rosnanotechnology, Inc., Niarmedic, Inc., Immafarma, Inc. Moscow, St. Petersburg, Russia
Cycle of lectures on the development of nano-vaccines for AD and BrCA
- Sept 2010: University of Arkansas Cancer Center, Arkansas, USA
Cancer-testis BORIS based dendritic cell vaccine for BrCA
- March 2011: 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), 9-13 March 2011, Barcelona, Spain (Invited speaker):
Alzheimer's Disease Epitope Vaccines
- March 2011: Lundbeck A/G, Copenhagen, Denmark
Epitope Vaccines Reduces AD-like Pathology in APP/Tg Mice
- March 2011: Lundbeck A/G, Copenhagen, Denmark

Alzheimer's Disease Epitope Vaccines based on DNA, peptides or recombinant Proteins

- October 2012 Alzheimer's Disease Research Center, UCLA, Los-Angeles, CA, USA
Alzheimer's Disease Active Vaccination Strategy: Targeting A β and Tau pathology in asymptomatic pre-AD subjects
- Sep 2015 Immunotherapeutic strategies to fight AD and metastatic BrCA
Mexico City, Senate of the Republic of Mexico
- Nov 2015 Active vaccination strategies to prevent and reverse Alzheimer's Disease (AD)
Keynote presentation on OMICS Vaccines and Vaccinations Congress, San-Francisco
- Dec 2015 Targeting Toll-Like Receptor 4 (TLR4) with pharmaceutical grade non-toxic agonist as a therapeutic strategy for metastatic breast cancer

Oral Presentations at Conferences (Not Including Poster Presentations)

- October 1975: 10th Meeting of USSR Young Immunologists: Dynamics of the antibody formation during cultivation immune mouse splenocytes *in vitro*
- October 1976: 11th Meeting of USSR Young Immunologists: The influence of temperature of incubation on antibody formation in the lymphatic cell cultures
- July 1978: Annual Meeting of the USSR Biochemistry Society, Leningrad, Russia: Differentiation of B-cells to AFC without division
- Dec 1979: USSR Academy of Medicine, Kiev: Increasing of the AFC and nIFC number in m mice immunized with T-dependent and T-independent antigens
- August 1980: Annual Meeting of Federation of European Biochemistry Societies (FEBS), Rome, Italy: Antigen-induced increase in the number of nonspecific immunoglobulin-forming cells *in vitro*
- Sept 1981: Annual Meeting of FEBS, Moscow, Russia: A sharp antigen-induced increase in the number of IFC in cultures
- April 1983: Second international Conference on Bone Marrow, Novosibirsk, USSR: The role of antigen-binding cells in the formation of AFC and IFC in living animals and in vitro
- Sept 1984: Annual Meeting of the USSR National Academy of Science(Section of Biology), Moscow : Idiotypic regulation of immune response to influenza virus PR/8
- Sept 1987: International Meeting of Epidemiology and immunology of Influenza Virus, Leningrad: Induction of immune response to influenza virus in splenocytes culture of mice

- October 1990: Annual Meeting of European Federation of Immunological Societies (EFIS), Edinburgh, Scotland: Antigen-binding B-lymphocytes involved in the formation AFC and IFC
- August 1992: Annual Meeting EFIS, Budapest, Hungary: The role of antigen-binding B lymphocytes in the specific and non-specific immune responses *in vivo* and *in vitro*
- Sept 1992: Vaccine 1992 Conf in Cold Spring Harbor Laboratory Meeting, USA: Genetic immunization: a novel method for vaccine development against HIV
- March 1992: Keystone Symposium, Molecular immunology of virus infections: Identification of a membrane antigen important for HTLV syncytia formation
- September 1993: Vaccines 1994 Conf, Cold Spring Harbor Laboratory Meeting, USA : Immune response in rabbits after inoculation with an HTLV-1 envelope DNA construct
- May 1994: 6th International Meeting of Retrovirology Association HTLV and Related Viruses, New-Jersey, USA: A novel 80kD antigen the HTLV-I/II putative fusogenic cellular receptor
- June 1994: Annual Meeting of European Federation of Immunological Societies (EFIS), Barcelona, Spain: Generation of monoclonal antibodies against a novel 80kD antigen the HTLV-I/II putative fusogenic cellular receptor.
- October 1995: 7th International Meeting of Retroviruses Paris, France: Monoclonal antibodies against 80kDa cellular antigen important HTLV infection.
- May 1996: Cambridge Symposia Tumor Vaccines, Taos NM, USA: Novel Genetic Approaches for Tumor Vaccines and Immunotherapy
- Sep 1997: Vaccines 1996, Cold Spring Harbor Laboratory Meeting, USA : HIV-2 expression vector generate cross strain humoral and cellular anti-HIV-2 as well as anti-SIV immune responses.
- April 1998 6-th International Expert Forum on Immunotherapy and Gene Therapy Florence, Italy: Expression of CD86 and MHC class I in the muscle tissue induce anti-viral CTLs
- May 1999 New Concepts in HIV Vaccine Developments at NIH/AVRC Workshop, Washington, USA: Inhibition of anti-HIV-1 cellular immune responses by C-domain of CD80 costimulatory molecule
- March 1999: 2nd International Conference on the Control of Infectious Diseases, Infectious Control World Organization, Minsk. Multicomponent DNA Vaccines and Immune Response
- July 2002 8th international conference for AD, Stockholm, Sweden:

(1) Adjuvant-dependent modulation of Th1/Th2 immune responses to immunization with β -amyloid peptide; (2) Generation of immune responses to A β immunization, using DNA immunization technique

- May 2003 6th International Conference AD/PD, Seville, Spain:
Conformation-specific polyclonal anti-A β_{42} antibodies generated in APP/Tg mice
- March 2005 7th International Conference AD/PD 2005, Sorrento, Italy:
Prototype AD Vaccine Utilizing the Immunodominant B cell epitope from amyloid- β and promiscuous T cell Epitope PADRE
- May 2006: AAI Boston, USA:
Induction of Potent Tissue Unrestricted Cancer Specific Immune Responses by Vaccination with a Novel Oncoinitiating Transcription Factor, BORIS
- July 2006: 3rd CTCF/BORIS Conference, South Carolina, USA.
Immune responses to a novel cancer-testis antigen, BORIS.
- August 2006: Alzheimer's Disease and Related Disorders, Madrid, Spain:
DNA-based Alzheimer's disease vaccine
- October 2007: 4th CTCF/BORIS Conference, Santander, Spain. Protection against challenge with breast cancer generated by vaccination with truncated CT-antigen, BORIS
- March 2007: 8th International Conference AD/PD, Salzburg, Austria:
The Second Generation of DNA-Based AD Vaccine
- August 2007: Biomedical Advanced Research and Development Authority (BARDA), Washington, DC, USA:
Generation of Single Platform Diagnostic Test for Category A and B Pathogens
- Sept 2007: 2nd Congress for Immunomediated diseases, Moscow, Russia
Prototype Alzheimer disease vaccines: Problems and solutions
- June 2008: DNA epitope vaccine prevents AD like pathology in 3xTg-AD mice and protects them from cognitive decline. International Conference on Prevention of Dementia.
Washington, DC, USA
- July 2008: International Conference on Alzheimer's Disease (ICAD-2008), Chicago, IL:
The novel strategy for generation of effective and safe Alzheimer's Disease vaccine based on conventional influenza virus vaccine modified to express A β_{1-11} .
- Dec 2008: International Society of Vaccine, DNA Vaccine 2008, Las-Vegas, USA:
DNA Epitope vaccine for AD.
- March 2009: 9th International Conference AD/PD, Prague, Czech Republic:

Third generation of epitope vaccine (EV): A new Strategy for A β immunotherapy

- July 2009: International Conference on Alzheimer's Disease (ICAD-2009), Vienna, Austria: Induction of rapid and robust anti-A β antibody production by reactivation of pre-existing memory Th cells generated from conventional vaccines
- March 2010: International Society of Vaccine, DNA Vaccine 2009, New Orleans, LA, USA:
1) Improvement of Alzheimer's Disease (AD) DNA Vaccine Efficacy by DNA Prime/Protein Boost Regimen in Mice and Rabbits;
2) DNA vaccine Based on Cancer-Testis Antigen, BORIS and IL21 molecular adjuvant in extremely effective for treatment of Metastatic Disease.
- April 2010: AACR 101st Annual Meeting, Washington, DC, USA
1) A Novel Cancer-Testis Antigen, BORIS Based Vaccine Delivered by Dendritic Cells is Effective against Metastatic Disease (*National Press Release*)
2) Multivalent VRP-based anti-tumor immunotherapy is an effective therapeutic strategy in a rat model of breast cancer.
- July 2010: International Conference on Alzheimer's Disease (ICAD-11, 2010), Alzheimer's Association, Honolulu, Hawaii, USA:
Exploiting prime-boost regimen and various delivery strategies to improve Alzheimer's Disease DNA vaccine efficacy
- Sept 2010: WPR Cancer Institute, UNAM, USA:
Cancer Immunotherapy Based on a Novel Cancer-Testis Antigen, BORIS
- Feb 2011 MiND UCI: Epitope Vaccines targeting a-syn and tau proteins
- July 2012: Alzheimer's Association International Conference (AAIC) Alzheimer's Association, Vancouver Canada, 2012, July 14-19. Translational Study: Refinement of DNA based Alzheimer's Disease (AD) Epitope Vaccine in Rabbits.
- Nov 2012: MultiTEP platform for targeting amyloid, data in mice, rabbits and monkeys: Alzheimer's Disease Research Forum (ADRF), UCLA
- July 2013: Immunogenicity of MultiTEP platform in various species: targeting amyloid, tau, and a-syn, as well as dual or triple vaccines: Pharmsinthes, St. Petersburg; NearMedic, Moscow
- August 2014: Aramanezumab, novel anti-Otau humanized Mab
Nanolek Inc., Los Angeles
- June 2014: Active and Passive vaccination for AD and PD
Nearmedic Plus, Inc and Immapharma, LLC, Moscow Russia
- June 2015 TLR4 agonist based immunotherapy of cancer
4IAMC congress plenary talk, Yerevan, Armenia

- June 2015 DNA Vaccines for Alzheimer's Disease
Satellite Symposium for 4IAMC congress
- Nov 2015 New strategies for AD vaccinations, Keynote presentation
OMICS 9th global Vaccines and Vaccinations
- Dec 2015 A novel TLR4 agonist for treating of metastatic BrCA disease
OMICS 9th global Vaccines and Vaccinations
- June 2016 AAIC 2016, Canada
- Jan 2017 JP Morgan Bio: Talk at Eli Lilly: MultiTEP as universal vaccine platform for neurodegenerative disorders.
- July 2017 AAIC 2017, London
- Jan 2017 JP Morgan Bio: Talk at Eli Lilly : MultiTEP as universal vaccine platform for neurodegenerative disorders.
- July 2017 AAIC2017 London

Clinical Studies

- January-August 2002: The effect of different preparations of Echinacea on human and murine immune systems.
- June-November 2002 The effects of NT Factor (phosphoglycolipid extract) on mitochondrial functions and mutation of mtDNA in elderly people.
- February 2003 -2005 Effect of TNP on HIV virus load in plasma and PBMC of infected patient (Clinical trial in China with Viral Genetics, Inc)
- January 2004-2008 Effect of TNP and HAART on HIV virus load in plasma and PBMC of infected patient (Clinical trial in South Africa with Viral Genetics, Inc)
- June 2009-Present Testing safety and toxicity of DNA epitope vaccine for Alzheimer's disease (IND for US FDA).

Publications in peer-reviewed journals *(Published abstracts are not presented and pls check Pubmed for various spelling of Agadjanyan MG names, such as Agadjanyan M, Agadjanian M, Agadjanian MG, Agadzhanian MG, Agadzanyan M, Agajanian, MG, Agajanian M)*

1. **Agadjanyan, M.G.** and Gurvich, A.E. Study of antibody formation during cultivation immune mouse splenocytes in vitro. Armenian J. of Biology 1976, 29: 3-10.
2. **Agadjanyan, M.G.** and Gurvich, A.E. Dependence of antibody formation in the lymphatic cell cultures from the temperature of incubation .Bull. Exp. Biol. Med. 1977, 12: 700-703.
3. **Agadjanyan, M.G.**,Gurvich,A.E., Grigoreva, O. Appearance of cells capable of being converted to antibody-forming cells without division at late stages of the immune process. Proceedings of the Academy of Science of the USSR. 1978, 242: 449-452.
4. Sidorova,E., **Agadjanyan, M.G.**, Korukova,A, Gurvich, A.E. Antigen-induced increase in the number of nonspecific immunoglobulin-forming cells in vitro. Bull. Exp. Biol. Med. 1980, 8: 64-66.
5. **Agadjanyan, M.G.**, Megrabyan,T., Sidorova, E. Increase in the AFC and nIFC number in mice immunized with T-dependent and T-independent antigens. Bull. Exp. Biol. Med. 1981, 8: 66-69.
6. Sidorova,E., **Agadjanyan, M.G.**, Korukova,A., Gurvich, A.E. A sharp antigen-induced increase in the number of cells secreting non-specific immunoglobulins in vitro. Immunol. Letters 1981, 3: 21-26.
7. **Agadjanyan, M.G.** and Sidorova,E. The role of antigen-binding receptors in the formation of specific and non-specific immunoglobulin. In 3 Soviet-Swiss Meeting, Ed. Academy of Science, USSR. 1983: 1, 144-148.
8. **Agadjanyan, M.G.**, Nesterenko, V., Megrabian, T. Inhibition of antigen-dependent nIFC by syngeneic anti-SRBC immunoglobulins. Bull. Exp. Biol. Med. 1985: 3, 328-330.
9. **Agadjanyan, M.G.**, Nesterenko,V., Megrabian,T. Inhibition of cells producing antigen-dependent non-specific immunoglobulins by isologous anti-erythrocyte immunoglobulins. Immunol. Letters. 1985, 9 :307-311.
10. **Agadjanyan, M.G.**, Megrabian,T., Sidorova, E. The role of antigen-binding cells in the formation of antibody and antigen dependent nonspecific immunoglobulin producers. Bull. Exp. Biol. Med. 1985, 9: 327-330.
11. Megrabian, T., **Agadjanyan, M.G.**, Zaritskaja,L., Sidorova, E. Formation of antigen-dependent nIFC in mice immunized with two T-independent-antigens. Bull. Exp. Biol. Med. 1985, 10, 451-454.
12. **Agadjanyan, M.G.** The mechanism of B-cell activation. In "Molecular and cellular regulation of infectious immunity" Ed. Academy of Medical Science, USSR, Moscow, 1985, 18-37.
13. **Agadjanyan, M.G.**, Smirnova, I. N., Sidorova, E. The dependence of the non-specific immunoglobulin producer formation on the doses of T-dependent and T-independent antigens. Bull. Exp. Biol. Med. 1986, 8: 206-208.
14. **Agadjanyan, M.G.**, Smirnova, I. N., Sidorova, E. The role of G₀- and G₁-splenocytes and antigen-binding lymphocytes in the production of antigen-dependent nonspecific immunoglobulins. Bull. Exp. Biol. Med. 1986, 11, 589-592.
15. **Agadjanyan, M.G.** Differentiation and activation of B-lymphocytes. Uspechi Sovr.Biol. 1987, 104, 55-70.
16. **Agadjanyan, M.G.** Activation of B-cells and mechanisms of T-B-lymphocytes interaction. Immunology (USSR). 1987, 3, 13-17.
17. Maklakov, A., Sidorova, E. **Agadjanyan, M.G.** Chac, J. Idiotypic regulation of immune response to influenza virus by syngeneic Ig conjugated with cellulose. Immunology (USSR). 1988 3, 40-42.
18. Gimmelfarb, E., **Agadjanyan, M.G.** The influence of unilateral nephrectomy on the degree of humoral immune response to T-independent antigen. Bull Exp. Biol .Med. 1988, 12: 702-704.

19. Logunova, N., Sidorova E.V., **Agadjanyan, M.G.** Identification of the cells secreting immunoglobulins and antibodies to influenza virus and polyvinylpyrrolidone by ELISA. *Immunology (USSR)* 1989, 2, 77-79.
20. **Agadjanyan, M.G.**, Maklakov, A., Sidorova, E. Induction of immune response to influenza virus in splenocytes culture of mice. *Immunology (USSR)*. 1989, 5, 86-88.
21. **Agadjanyan, M.G.** Antiidiotypic antibody as new generation of vaccine. *Voprosi Virusologii (USSR, Czech)*. 1989, 5, 637-638.
22. **Agadjanyan, M.G.**, Sidorova, E. The role of antigen-binding B-lymphocytes in the formation of cells producing antigen-dependent nonspecific immunoglobulins. *Immunol. (USSR)*. 1991, 1, 66-68.
23. **Agadjanyan, M.G.**, Sidorova, E., Bilady, I. The inhibition of the immune response by respiratory viruses in mice, *Bull. Exp. Biol. Med.* 1991, 5, 510-512.
24. **Agadjanyan, M.G.** and Sidorova, E. Role of antigen-binding B-lymphocytes in the formation of antigen-dependent nonspecific immunoglobulin-forming cells. *Biomed. Science, London*, 1991, 2, 361-366
25. Pichugin, A., **Agadjanyan, M.G.**, Karpova, O, Ataulachanov, R.I. Using cellular ELISA and FACS for detection of the preparation inhibiting the interaction between HIV and CD4 receptor. *Immunology (Russia)*. 1992, 4: 12-15.
26. Bakay, M., Beladi, I., Berencsi, K., Sidorova, E., **Agadjanyan, M.G.**, Fachel, J., Erdei, J. Immunoenhancement and suppression induced by adenovirus in chicken. *Acta Virol.* 1992, 36: 269-276
27. Wang, B., Ugen, K.E., Srikantan, V., **Agadjanyan, M.G.**, Dang, K., Sato, A.I., Refaeli, Y., Boyer, J., Williams, W.V., Weiner, D.B. Gene inoculation generates immune responses against human immunodeficiency virus type I. *Proc. Nat. Acad. Sci., USA*. 1993, 90: 4156-4160.
28. Ugen, K.E., Refaeli, Y., Ziegner, U., **Agadjanyan, M.G.**, Satre, M., Wang, B., Sato, A., Williams, W.V., Weiner, D.B. Generation of monoclonal antibodies against the amino region of gp120 which elicits antibody dependent cellular cytotoxicity. "Modern approaches to new vaccines including prevention of AIDS" *Vaccines*" Ed. Cold Spring Harbor Laboratory 1993, 215-221.
29. Wang, B., Ugen, K.E., Srikantan, V. **Agadjanyan, M.G.**, Dang, K., Williams, W. V., Weiner, D.B. Genetic immunization: a novel method for vaccine development against HIV In "Modern approaches to new vaccines including prevention of AIDS " *Vaccines*" Ed. Cold Spring Harbor Laboratory 1993, 143-150.
30. Wang, B., **Agadjanyan, M.G.**, Srikantan, V., Ugen, K., Williams, W.W., Weiner, D.B. Molecular cloning, expression and biological characterization of an HTLV-II envelope glycoprotein: HIV-I expression is permissive for HTLV-II induced cell fusion. *AIDS and Human Retroviruses*. 1993, 9: 849-860.
31. Wang, B., Boyer, J., Srikantan, V., Coney, L., Carrano, R., Phan, K., , Merva, M., Dang, K., Gilbert, L., **Agadjanyan, M.G.**, Ugen, K.E., Williams, W.V., Weiner, D.B. DNA Inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. *DNA and Cell Biology*. 1993, 12: 799-805.
32. **Agadjanyan, M.G.**, Ugen K., Wang B., Williams, W.W., Weiner, D.B. Identification of an 80 kD membrane glycoprotein important for HTLV-I and HTLV-II syncytium formation and infection. *J. Virology*. 1994, 68: 485-493.
33. **Agadjanyan, M.G.**, Ugen K., Wang B., Villafana, T., Merva, M., Petrushina, I., Williams, W.W., Weiner, D.B. DNA inoculation with an HTLV-I envelope DNA construct elicits immune responses in rabbits. In: *Vaccines '94: Modern Approaches to New Vaccines Including Prevention of AIDS* (Chanock, R.M., Ginsberg, H.S., Brown, F., and Lerner, R.A., eds). Cold Spring Harbor Laboratory Press pp 47-53.

34. Wang B., Boyer J., Ugen K., Merva, M., Dang, K., **Agadjanyan, M.G.**, Williams, W.W., Weiner, D.B., Coney, L., Carrano, R. Analysis of antigen-specific immune responses induced through in vivo genetic inoculation. In: Vaccines '94: Modern Approaches to New Vaccines Including Prevention of AIDS (Chanock, R.M., Ginsberg, H.S., Brown, F., and Lerner, R.A., eds). Cold Spring Harbor Laboratory Press pp 83-90.
35. Ugen, K.E., Wang, B., Ziegner, U., Srikantan, V., **Agadjanyan, M.G.**, Boyer, J., Cotropia, J. Williams, W. V. and Weiner, D.B. Vertical transmission of human retroviral infections: immunological considerations. Archives of STD and HIV Research 1994, 8: 283-292.
36. Ugen, K.E., Wang, B., Ayyavoo, V., **Agadjanyan, M.G.**, Boyer, J., Li, F., Kudchodkar, S., Lin, J., Merva, M., Williams, W.V. and Weiner, D.B. 1994. DNA inoculation as a novel vaccination method against human retroviruses with rheumatic disease associations. Immunologic Research, 1994, 13: 154-162
37. Coney, L., Wang, B., Ugen, K.E., Boyer, J., McCallus, D., Srikantan, V., **Agadjanyan, M. G.**, Patchuk, C., Merva, M., Newman, M, Williams, W.V., and Weiner, D.B. Facilitated DNA inoculation induces anti-HIV-1 immunity *in vivo*. Vaccine, 1995, 12: 1545-1550.
38. **Agadjanyan, M.G.**, Ugen K.E., Wang, B., Kudchodkar, S., Arthur Cho, Merva, M., Boyer, J.D., Li, F. Williams, W.V. and Weiner, D.B. Elicitation of immune responses in rodents after DNA inoculation with an HTLV-I envelope glycoprotein, expressing construct: a model for vaccination efficacy. In Vaccine's 95. Molecular Approaches to the Control of Infectious Diseases (Brown, F., Chanock, R.M., Ginsberg, H.S and Norrby, E., eds.). Cold Spring Harbor Laboratory Press, pp. 129-134.
39. Wang, B., Boyer, J.D., Ugen, K.E., Srikantan, V. **Agadjanyan, M.G.**, Williams, W.V., Newman, M., Coney, L., Carrano, R. and Weiner, D.B. 1995. Nucleic acid immunization against HIV-1: induction of protective *in vivo* immune responses. AIDS 9: S159-S170.
40. Wang, B., Boyer, J., Srikantan, V., Ugen, K., Gilbert, L., Phan, C., Dang, K., Merva, M., **Agadjanyan, M. G.**, Newman, M., Carrano, R., McCallus, D., Coney, L., Williams, W.V. and Weiner, D.B. 1995. Induction of humoral and cellular immune responses to the human immunodeficiency type I virus in non-human primates by *in vivo* DNA inoculation. Virology 221 : 102-112.
41. Wang, B., Boyer, J., Srikantan, V., Ugen, K., **Agadjanyan, M.G.**, Merva, M., Gilbert, L., Dang, K., McCallus, D., Moelling, K, Carrano, R., Williams, W.V. and Weiner, D.B. 1995. DNA inoculation induces cross clade anti-HIV-1 responses. 1996 Annals of the New York Academy of Sciences, 772, 186-197
42. Boyer, J., Wang, B., V., Ugen, K., **Agadjanyan, M.G.**, Javadian A., Frost P., Dang K., Carrano R.A., Ciccarelli R., Coney L., Williams W.W., and Weiner, D.B. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. 1996. J. Med. Primatol., 25, 242-250
43. Mahalingam S., MacDonald B., Ugen K., Ayyavoo V., Williams W.W., **Agadjanyan, M.G.**, Weiner D.B. In vitro and in vivo tumor growth suppression by HIV-1 Vpr. DNA and Cell Biol., 1997, 16, 137-143
44. Ugen, K.E., Boyer, J, **Agadjanyan, M.G.**, Wang, B., Javadian, A., Nyland S., Coney L, McCallus, D., Williams, W., and Weiner, D.B. Site specific immune responses generated in Chimpanzees after DNA inoculation with HIV-1 envelope expressing constructs. In Vaccine's 96. Cold Spring Harbor Laboratory Press. 61-65.
45. Ugen, K.E., Boyer, J, Wang, B., Bagarazzi, M., Javadian, A., Frost, P., merva M., **Agadjanyan, M.G.**, Nyland S., Williams, W., Coney, L, Ciccarelli R., and Weiner, D.B. Nucleic acid immunization of chimpanzee as a prophylactic /immunotherapeutic vaccination model for HIV-1: Prelude to a clinical trial. Vaccine , 1997, 15, 927-929.
46. Ugen, K.E., Boyer, J., **Agadjanyan, M.G.**, Wang, B., Nyland, S., Carmack, B., MacGregor, R.R., Gluckman, S., Bagarazzi, M., Coney, L., Carrano, R., Ginsberg, R., Ciccarelli, R. and D. B. Weiner. 1997. Facilitated

nucleic acid vaccination of humans with an HIV-1 expressing DNA plasmid boosts immune responses against viral proteins. In *Vaccine's 97*. Cold Spring Harbor Laboratory Press, pp 145-149.

47. **Agadjanyan, M.G.**, Trivedi, N., Kim J., Levine W., Kuchkadar S., Boyer J., Ugen K., Weiner D.B. 1997. HIV-2 expression vector generate cross strain humoral and cellular anti-HIV-2 as well as anti-SIV immune responses. In *Vaccine's 97*. Cold Spring Harbor Laboratory Press. pp. 131-135.

48. Boyer, J., Ugen, K., Wang, B., V., **Agadjanyan, M.G.**, Gilbert, L., Bagarazzi, M., Chattergoon, M., Frost, P., Javadian A., Williams W.V., Ciccarelli R., mcCallus D., Coney L., and Weiner, D.B. Induction of protective humoral and cellular immune responses to HIV-1 in chimpanzees by in vivo DNA inoculation. *Nature Medicine*, 1997, 3, 526-532.

49. **Agadjanyan, M.G.**, Westerink J., Carey L., Luo P., Blaszczyk-Thurin M., Steplewski Z., Weiner D.B., Kieber-Emmons T. Peptide mimicry of carbohydrate epitopes on Human Immunodeficiency Virus. *Nature Biotech.*, 1997, 15, 547-551.

50. Yusibov V., Modelska A., Steplewski K., **Agadjanyan, M.G.**, Weiner D.B., Hooper C., Koprowski H. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and human immunodeficiency virus-1. *Proc. Nat. Acad. Sci. USA*, 1997, 94, 5784-5788.

51. Kim, J.J., Bagarazzi, M., Hu Y., N. Traverdi, Chattergoon, M., Dang, K., Mahalingam S., Boyer, J., **Agadjanyan, M.G.**, Weiner, D.B. Engineering of in vivo immune responses to DNA immunozation via co-delivery of costimulatory molecule genes. *Nature Biotech.*, 1997, 15, 641-646.

52. Wang B., Dang K., **Agadjanyan, M.G.**, B., Srikantan V., Li F., Ugen K., Boyer J., Merva M., Williams W.V., and Weiner D.B. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. *Vaccine* 1997, 15, 821-825

53. **Agadjanyan, M.G.**, Wang, B., Nyland S., Weiner, D.B., and Ugen, K.E. DNA plasmid based vaccination against the oncogenic human T-cell leukemia virus type 1. 1997. *Current Topics in Microbiology and Immunology* 1997, 226, 177-194.

54. **Agadjanyan, M.G.**, Trivedi N., Levine W., Kuchkadar S., K. Ugen, J.Kim, Weiner D.B. Characterization of immune responses against HIV-2 and SIVmac after inoculation of mice with HIV-2 expression vector. 1977. *AIDS and Human Retroviruses* 1997, 13, 1561-1572.

55. Boyer, J., Ugen, K., Chattergoon, M, Wang, B., Shah A., **Agadjanyan, M.G.**, Bagarazzi M.L., Javadian A., Carrano R., Coney L., Williams W.V., and Weiner, D.B. DNA vaccination as anti-HIV immunotherapy in infected chimpanzees. *J. Infectious Deseases*, 1997, 176, 1501-1509.

56. Kieber-Emmons T., Luo P., Qiu J., **Agadjanyan, M.G.**, Carey L., Hutchins W., Westerink M.A., Steplewski Z., Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. *Hybridoma*. 1997, 16, 3-10.

57. Kim, J.J., Trivedi, Mahalingam S., Morrison L., Tsai A., Chattergoon, M., Dang, K., Chalian A., Boyer, J., Kieber-Emmons T, **Agadjanyan, M.G.**, Weiner, D.B. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. *Eur. J. Immunol.*, 1998, 28, 1089-1103.

58. Kim, J.J., Nottingham, M.A., Maldonado, M.A., Williams, W.V., Weiner, D.B., **Agadjanyan, M.G.** CD86, but not CD80, is important for the induction of MHC class I restricted anti-HIV-1 CTL. 12th World AIDS Conference, Geneva (Switzerland), June 28-July 3, 1998, Monduzzi Editore, Appendix 1998, 5, 29-34.

59. **Agadjanyan, M.G.**, Chattergoon M., Petrushina I., M. Bennett, J.Kim., K. Ugen, Weiner D.B. Monoclonal antibodies define a cellular antigen involved in HTLV-I Infection. *Hybridoma*, 1998, 17, 9-19.

60. Kim, J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., Dang K., Hu Y., Kazahaya K., Bennett M., Denchev T., Willson D.M., Chalian A., Boyer, J., **Agadjanyan, M.G.**, Weiner, D.B. CD8 positive T-cells influence antigen-specific immune responses through the expression of chemokines. *J. Clin. Invest.*, 1998, 102, 1-13.
61. Kim, J.J., Trivedi, Mahalingam S., Morrison L., Tsai A., Chattergoon, M., Dang, K., Patel M., Ahn K., Chalian A., Boyer, J., Kieber-Emmons T, **Agadjanyan, M.G.**, Weiner, D.B. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. *Oncogene*, 1998, 17, 3125-3135.
62. Kim J.J., Nottingham L.K., Wilson D.M., Bagarazzi M.L., Tsai A., Morrison L.D., Javadian A., Chalian A.A., **Agadjanyan, M.G.**, Weiner DB. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. *Vaccine* 1998, 16, 1828-1835.
63. Luo P., **Agadjanyan, M.G.**, Qiu J., Westerink M.A., Steplewski Z., Kieber-Emmons T., Antigenic and immunological mimicry of peptide mimitopes of Lewis carbohydrate antigens. *Mol. Immun.*1998, 35, 865-879.
64. Kim, J.J., Simbiri K.A., Sin, J.I., Dang, K., Oh, K., Dentchev, T., Lee D., Morrison, L., Tsai A., Chattergoon, M., Dang, K., Nottingham, L.K., Chalian, A., McCallus, D., Ciccarelli, R., **Agadjanyan, M.G.**, Weiner, D.B. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. *J. Interferon and Cytokine research*, 1999, 19, 77-84.
65. **Agadjanyan, M.G.**, Kim J., Trivedi N., Willson D., Monzavi-Karbassi B., Morrison L., Nottingham L., Dentchev T., Chalian A., Moldonado M.A., Williams W.V., Weiner D.B., CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses *in vivo*. *J. Immunology* 1999, 162, 3417-3427
66. Kim, J.J., Tsai, A., Nottingham, L.K., Morrison, L., Cunning, D.M., Oh J., Lee D. J., Dang, K., Dentchev, T., Chalian, A., **Agadjanyan, M.G.**, Weiner, D.B. Intracellular adhesion molecule-1 modulates B-chemokines and directly costimulates T-cells *in vivo*. *J. Clinical Investigation*, 1999, 103, 869-877
67. Kim, J.J., Nottingham, L.K., Tsai, A., Lee, D. J., Dang K., Maguire, H.C., Oh J., Dentchev, T., Manson, K.H., Wyand, M.S., **Agadjanyan, M.G.**, Ugen, K.E., Weiner, D.B. Antigen specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN- γ IL-12, or IL-18 gene adjuvants. *J. Med. Primotol.*, 1999, 28, 214-223.
68. Viveros M., Dickey, C., Cotropia J., Gevorkian G., Larralde C., Broliden K., Levi, M., Burgess, A., **Agadjanyan M.G.**, Ugen K.E. Characterization of a novel HIV-1 neutralizable epitope within the immunodominant region of gp41. *Virology*, 2000, 270, 135-145.
69. Bennett, M. and **Agadjanyan, M.G.** HTLV-1 and 2 infections: Immunological and molecular aspects. Kluwer Academic/Plenum Publishers, NY, 2000, 87-107.
70. Dickey, C., Ziegner, U., **Agadjanyan M.G.**, Srikantan, V., Rafaely, J., Prabhu, A., Sato, A., Williams, W.V., Weiner, D.B., Ugen K.E. Biologically active murine monoclonal antibodies against the amino region of HIV-1 gp120: Isolation and Characterization. *DNA and Cell Biology*, 2000, 19, 243-252.
71. Vasilevko, V., Ghochikyan, A., Holterman, M.J., **Agadjanyan, M.G.** CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4⁺ T cell proliferation after activation with sub-optimal doses of PHA. *DNA and cell Biology*, 2002, 21, 137-149.
72. Petrushina, I., Tran, M., Sadzikava, N., Ghochikyan, A., Vasilevko, V., Cribbs, D.H., **Agadjanyan, M.G.** Importance of IgG2c isotype in the immune response to β -amyloid in APP/Tg mice. *Neuroscience Letters*, 2003, 338, 5-8.

73. Cribbs, D.H., Ghochikyan, A., Vasilevko, V., Tran, M., Petrushina, I., Sadzikava, N., Babikyan, D., Kessler, P.J., Kieber-Emmons, T., Cotman, C.W., **Agadjanyan, M.G.** Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β -amyloid. *Int. Immunol.*, 2003, 15, 505-514.
74. **Agadjanyan, M.G.**, Vasilevko, V., Ghochikyan, A., Berns, P., Kessler, P.J., Settineri, R.A., Nicolson, G.L., Nutritional supplement (NT Factor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. *J. Chronic Fatigue Syndr.*, 2003, 11, 23-36.
75. **Agadjanyan, M.G.**, Chattergoon, M., Holterman, M.J., Monzavi-Karbassi, B., Kim J., Dentchev, T., Willson, D., Ayyavoo, V., Montaner, L.J., Kieber-Emmons, T., Sekaly, R-P., Weiner, D.B. Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. *J. Immunology*, 2003, 171, 4311-4319.
76. Vasilevko, V., Ghochikyan, A., Sadzikava, N., Petrushina, I., Tran, M., Cohen, E., Kessler, P.J., Cribbs, D.H., Nicolson, G.L., **Agadjanyan, M.G.** Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors. *Clin. Exp. Metastasis*, 2003, 20, 489-98.
77. Ghochikyan, A., Vasilevko, V., Petrushina, I., Movsesyan, N., Babikyan, D., Tian, Sadzikava, N., W., Ross, T. M., Head, E., Cribbs, D.H., and **Agadjanyan, M.G.** Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. *Eur. J. Immunol.*, 2003, 33, 3232-3241.
78. Gevorkian, G., Petrushina, I., Manoutcharian, K., Ghochikyan, A., Acero, G., Vasilevko, V., Cribbs, D., **Agadjanyan, M.G.** Detection of conformational antigenic determinants mimicking fibrillar β -amyloid. *J. Neuroimmunology*, 2004, 156, 10-20.
79. **Agadjanyan, M.G.**, A., Ghochikyan, I., Petrushina, V., Vasilevko, N., Movsesyan, M., Mkrtychyan, T., Saing, D.H., Cribbs, D.H. 2004. Prototype Alzheimer's disease vaccine utilizing the immunodominant B cell epitope from β -amyloid and promiscuous T cell epitope PADRE. *J. Immunology*, 2005, 174, 1580-1586.
80. Cribbs, D.H. & **Agadjanyan, M.G.** Immunotherapy for Alzheimer's Disease: Potential problems and possible solutions. *Current Immunology Reviews* 2005, 1, 139-155
81. Ghochikyan, A., Mkrtychyan, M., Petrushina, I., Movsesyan, N., Karapetyan, A., Cribbs, D.H., **Agadjanyan, M.G.** Prototype Alzheimer's Disease epitope vaccine induced strong Th2-type anti-A β antibody response with Alum to Quil A adjuvant switch. *Vaccine*, 2006, 24, 2275-2282
82. Head, E., Barrett, E.G., Murphy, P.M., Das, P., Nistor, M., Sarsoza, F., Glabe, C.C., Kaye, R., Milton, S., Vasilevko, V., Milgram, N.W., **Agadjanyan, M.G.**, Cribbs, D.H., Cotman, C.W., Immunization with fibrillar A β ₁₋₄₂ in young and aged canines: Antibody Generation and Characteristics, and effects on CSF and Brain A β . *Vaccine*, 2006, 24, 2824-2834
83. Loukinov, D., Ghochikyan, A., Mkrtychyan, M., Ichim, T., Lobanenko, V., Cribbs, D., **Agadjanyan, M.** Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. *J. Cell. Biochem.*, 2006 98, 1037-1043.
84. Ghochikyan, A., Petrushina, I., Lees, A., Movsesyan, N., Karapetyan, A., **Agadjanyan, M.G.**, Cribbs, D.H. Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. *DNA Cell. Biol.* 2006, 10, 571-580.
85. Parachikova, A., **Agadjanyan, M.G.**, Cribbs, D.H., Blurton-Jones, M., Perreau, V., Rogers, J., Beach, T.G., Cotman, C.W. Inflammatory changes parallel the early stages of Alzheimer disease. *Neurobiol. Aging*. 2006 28, 1821-1833

86. Zhong, Z., Kuszneruk, K.P., Popov, I.A., Riordin, N.H., Izadi, H., Yijian, L., Sher., S., Szczurko, O.M., **Agadjanyan, M.G.**, Tullis, R.H., Harandi., A., Reznik, B.N., Mamikonyan, G.V., Ichim, T.E. Induction of antitumor immunity through xenoplacental immunization. *J. Transl. Med.* 2006, 25; 4-22.
87. Ghochikyan, A., Mkrtichyan, M., Loukinov, D., Mamikonyan, G., Movsesyan, N., Ichim, T.E., Lobanenkov, V.V., Cribbs, D.H., **Agadjanyan, M.G.** Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. *J. Immunol.*, 2007, 178, 566-73.
88. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiryakin A., Glabe C., Gribbs D.H., **Agadjanyan M.G.** Anti-A β_{1-11} antibody binds to different β -amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. *J Biol Chem*, 2007, 282, 22376-22386
89. Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, **Agadjanyan MG** Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. *J. Neurosci.* 2007, 27, 12721-12731
90. Mkrtichyan, M., Ghochikyan, A., Movsesyan, N., Karapetyan, A., Begoyan, G., Glenn, G.M., Ross, T.M., **Agadjanyan, M.G.**, Cribbs, D. H. Immunostimulant Adjuvant Patch Enhances Humoral and Cellular Immune Responses to DNA Immunization. *DNA Cell Biol.* 2008, Volume 27(1); 19-24;
91. Mkrtichyan, M, Ghochikyan, A., Loukinov, D., Davtyan, D, Ichim, T.E. Cribbs, D.H., Lobanenkov, V.V. and **Agadjanyan, M.G.** DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. *Gene Therapy* 2008, 15:61-64
92. Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, **Agadjanyan MG**, Reznik BN. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS *Biochem Biophys Res Commun*, 2008, 370, 109-112.
93. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina M, Davtyan H, Olkhanud P, Head E, Biragyn A, Cribbs DH, **Agadjanyan MG**. Prototype DNA epitope vaccine prevents behavioral impairment and AD-like pathology in 3xTg-AD mouse model without inducing cerebral hemorrhages *PLoS One*, 2008, 3, 5, e2124
94. Mamikonyan G, Kiyatkin A, Movsesyan N, Mkrtichyan M, Ghochikyan A, Petrushina I, Hwang J, Ichim T, **Agadjanyan MG**. Detection of the Active Components of Calf Thymus Nuclear Proteins (TNP), Histones that are Binding with High Affinity to HIV-1 Envelope Proteins and CD4 Molecules” *Current HIV Research*, 2008, 6, 318-326
95. Movsesyan N, Mkrtichyan M, Petrushina I, Ross T, Cribbs DH, **Agadjanyan MG**, Ghochikyan A. Generation of functional anti-amyloid antibodies after immunization with DNA encoding multiple copies of Ab-peptide immunogen fused with C3d. *Journal of Neuroimmunology*, 2008, 205, 57-63.
96. Petrushina I., Ghochikyan A., Mkrtichyan M., Mamikonyan G., Movsesyan N., Ajdari R., Vasilevko V., Karapetyan A., Lees A., **Agadjanyan MG.**, Cribbs DH. Mannan-A β_{28} conjugate prevented A β -plaque deposition, but increased microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice, *Journal of Neuroinflammation*, 2008, 5, 42-49.
97. Cribbs DH and **Agadjanyan MG**. Active and passive A β -immunotherapy: preclinical and clinical studies and future directions: part I/II. *CNS Neurol Disord Drug Targets*, 2009, 1:1-16.

98. **Agadjanyan M.G.** and Cribbs D.H. Active and passive A β -immunotherapy: preclinical and clinical studies and future directions: part I/II. *CNS Neurol Disord Drug Targets*, 2009, 2:82-87.
99. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, **Agadjanyan MG**, Ghochikyan A. 2010. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. *Gene Ther.* 17(2):261-71.
100. Movsesyan N, Davtyan H, Mkrtichyan M, Petrushina I, Tiraturyan T, Ross TM, **Agadjanyan MG**, Ghochikyan A, Cribbs DH. 2010. Low concentrations of anti-Abeta antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. *Hum Gene Ther.*, 2010, 21(11): 1569-1576.
101. Robert R, Lefranc MP, Ghochikyan A, **Agadjanyan MG**, Cribbs DH, Van Nostrand WE, Wark KL, Dolezal O. Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide. *Mol. Immunol.*, 2010, 48(1-3):59-72.
102. Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, **Agadjanyan MG**. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. *Cell Immunol.* 2011;270 (2):188-97.
103. Davtyan, H., Ghochikyan, A., Cadagan, R., Zamarin, D., Petrushina, I., Movsesyan, N., Martinez-Sobrido, L., Albrecht, RA., García-Sastre, A., **Agadjanyan, MG**. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. *J. Translational Med.*, 2011, 9:127
104. de Necochea-Campion R., Ghochikyan A., Josephs S.F., Zacharias S., Woods E., Karimi-Busheri F., Alexandrescu D.T., Chen C.S., Agadjanyan M.G., Carrier E. Expression of the epigenetic factor BORIS (CTCF) in the human genome. *J Transl Med.* 2011, 9:213.
105. Ghochikyan, A. and **Agadjanyan, M.G.** CAD-106, a beta-amyloid-based immunotherapeutic for Alzheimer's disease, Review in Thomson Reuters Cortellis 2012, May 9
106. Davtyan, H., Ghochikyan, A., Movsesyan, N., Ellefsen, B., Petrushina, I., Cribbs DH, Hannaman, D., Evans, CF, **Agadjanyan, MG**. Delivery of a DNA vaccine for Alzheimer's disease by electroporation or gene gun generates potent and similar immune responses. *Neurodegener Dis.* 2012, 10:261-4.
107. Ghochikyan A, Davtyan H, Petrushina I, Hovakimyan A, Movsesyan N, Davtyan A, Kiyatkin A, Cribbs DH, and **Agadjanyan MG**. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. *Hum Vaccin Immunother.* 2013 May;9(5):1002-10. doi: 10.4161/hv.23875. Epub 2013 Feb 11. PMID:23399748
108. Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A.M., Movsesyan, N., Kiyatkin, A., Rasool, S., Larsen, S.A., Madsen, P.J., Wegener, K.M., Ditlevsen, D.K., Cribbs, D.H., Pedersen, L.O., **Agadjanyan, M.G.**. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. *J. Neurosci.*, *J Neurosci.* 2013, 33:4923-34.
109. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, **Agadjanyan M.G.**, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric a β , and frank neuronal loss. *J Neurosci.* 2013, 33:6245-56
110. Evans C.F., Davtyan H, Petrushina I., Hovakimyan A., Davtyan A., Hannaman D., Cribbs D.H., **Agadjanyan M.G.**, Ghochikyan A. // Epitope-based DNA vaccine for Alzheimer's disease: translational

study in macaques. *Alzheimers Dement.* 2014 May;10 (3):284-95. *Alzheimers Dement.* 2014 May;10(3):284-95. doi: 10.1016/j.jalz.2013.04.505. Epub 2013 Jul 31. PMID: 23916838

111. Ghochikyan A, Davtyan A, Hovakimyan A, Davtyan H, Poghosyan A, Bagaev A, Ataulakhanov RI, Nelson EL, **Agadjanyan MG**. Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy. *Clin Exp Metastasis.* 2014 Feb;31(2):185-98. doi: 10.1007/s10585-013-9619-0. Epub 2013 Oct 6. PMID: 24096737

112. Ghochikyan A., Petrushina I., Davtyan H., Hovakimyan A., Saing T., Davtyan A., Cribbs D.H., **Agadjanyan M.G.**, Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α -synuclein: Feasibility study. *Neurosci Lett.* 2014 Feb 7;560:86-91. doi: 10.1016/j.neulet.2013.12.028. Epub 2013 Dec 19. PMID: 24361548

113. Davtyan H., Ghochikyan A., Hovakimyan A., Petrushina I., Yu J., Flyer D., Madsen P.J., Pedersen L.O., Cribbs D.H., **Agadjanyan M.G.**, Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. *J Neuroimmunol.* 2014 Mar 15;268(1-2):50-7. doi: 10.1016/j.jneuroim.2014.01.002. Epub 2014 Jan 15. PMID: 24507620

114. Davtyan H., Bacon A., Petrushina I., Zagorski K., Cribbs D.H., Ghochikyan A., **Agadjanyan M.G.**, Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease Epitope Vaccines. *Hum Vaccine& Immunother.* 2014 Feb 13;10(5):1-8. *Hum Vaccin Immunother.* 2014 May;10(5):1248-55. doi: 10.4161/hv.27882. Epub 2014 Feb 13. PMID: 24525778

115. Davtyan H, Ghochikyan A, Petrushina I., Hovakimyan A., Davtyan A., Cribbs D.H., **Agadjanyan M.G.**, MultiTEP platform-based AD epitope vaccine activates broad repertoire of T helper cells in non-human primates. *Alzheimers Dement.* 2014 May; 10(3):271-83. doi: 10.1016/j.jalz.2013.12.003. Epub 2014 Feb 20. PMID: 24560029

116. Davtyan H, Hovakimyan A., Zagorski K., Davtyan A., Petrushina I., Agdashian D., Murthy V., Cribbs D.H., **Agadjanyan M.G.**, Ghochikyan A, BTX AgilePulse^{MT} System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine. *Curr. Gene Ther.* 2014;14(3):190-9. PMID: 24867066

117. Davtyan H, Ghochikyan A, Hovakimyan A, Davtyan A, Cadagan R, Marleau AM, Albrecht RA, García-Sastre A, **Agadjanyan MG**. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti- β -amyloid antibody responses in mice with pre-existing virus specific memory. *J. Neuroimmunol.* 2014 Dec 15;277(1-2):77-84. doi: 10.1016/j.jneuroim.2014.10.002. Epub 2014 Oct 16. PMID: Select item 25455094

118. Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tikhvatulin A, Davtyan H, Shcheblyakov D, Logunov D, Chulkina M, Savilova A, Trofimov D, Nelson EL, **Agadjanyan MG**, Ataulakhanov RI. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax[®], as a therapeutic strategy for metastatic breast cancer. *J Transl. Med.* 2014 Nov 29;12(1):322. [Epub ahead of print] PMID: 25432242

119. **Agadjanyan MG**, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. *Alzheimers Dement.* 2015 Jul 17 [Epub ahead of print] PMID: 26192465

120. Davtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, Kazarian K, Cribbs DH, Petrovsky N, **Agadjanyan MG**, Ghochikyan A. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based

dual and single vaccines induce high-titer antibodies against various forms of tau and A β pathological molecules. *Sci Rep.* 2016 Jul 1;6:28912, PMID: 27363809

121. Petrushina I., Davtyan, H. Hovakimyan, A. Davtyan, A. Passos, G.F., Cribbs, D.H., Ghochikyan, A., **Agadjanyan, M.G.** Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of b-Amyloid in an Animal Model of Alzheimer's Disease. *Mol Ther.* 2017 Jan 4;25(1):153-164. doi: 10.1016/j.ymthe.2016.10.002. Epub 2017 Jan 4. PMID: 28129111

122. Davtyan, H., Chen, W.W., Zagorsky, K., Davis, J., Petrushina, I., Cribbs, D.H., **Agadjanyan, M.G.**, Blurton-Jones, M., Ghochikyan, A. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. *Vaccine*, 2017 Apr 11;35(16):2015-2024. doi: 10.1016/j.vaccine.2017.03.020. Epub 2017 Mar 18. PMID: 28320590

123. Davtyan H, Zagorski K, Petrushina I, Kazarian K, Goldberg NRS, Petrosyan J, Blurton-Jones M, Masliah E, Cribbs DH, **Agadjanyan MG**, Ghochikyan A. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. *Neurobiol Aging.* 2017 Aug 10. pii: S0197-4580(17)30261-0. doi: 10.1016/j.neurobiolaging.2017.08.006. [Epub ahead of print] PMID: 28870518

124. **Agadjanyan MG**, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, Davis J, Bon C, Blurton-Jones M, Cribbs DH, Ghochikyan A. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. *Mol Neurodegener.* 2017 May 5;12(1):33. doi: 10.1186/s13024-017-0172-1. PMID: 28472993